mTOR inhibitorFDA-approvedSecond-line
Everolimus
How it works
Blocks the mTOR pathway on cancer cells, preventing cell growth and division.
Cancer types
Breast Cancer— HER2-positive
Efficacy
Studies show that everolimus can improve progression-free survival in HR-positive patients with advanced breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Study of Everolimus and Hormone Therapy in High-Risk Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Everolimus May Help Some Women with Advanced Breast Cancer | Breast Cancer | observational | Median real-world progression-free survival was 5.0 months for patients exposed to everolimus vs 4.3 months for endocrine therapy alone. | Source → |
| Everolimus After Alpelisib in Hormone Receptor-positive Metastatic Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Everolimus Effectiveness in Rare Tumors Varies by Genetic Pathway | Pancreatic Cancer | observational | Alterations in the PI3K/AKT/mTOR pathway were associated with a higher disease control rate (85.7% vs. 28.6%); | Source → |
| Combining Everolimus and T-DM1 May Help Treat HER2-Positive Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Everolimus Side Effect: Rare Case of Bleeding in the Colon | Pancreatic Cancer | observational | — | Source → |
| Everolimus with Exemestane Shows Promise in Advanced Breast Cancer | Breast Cancer | observational | The median progression-free survival was 18.0 months and the overall response rate was 22.7%. | Source → |
| Everolimus and Endocrine Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | The clinical benefit rate was 66.7% in the everolimus group and 37.0% in the control group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.